Publicações científicas

Amyloid PET in neurodegenerative diseases with dementia

Camacho V (1), Gómez-Grande A (2), Sopena P (3), García-Solís D (4), Gómez Río M (5), Lorenzo C (6), Rubí S (7), Arbizu J (8); por el Grupo de Neuroimagen SEMNIM.

(1) Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España.
(2) Servicio de Medicina Nuclear, Hospital 12 de Octubre, Madrid, España.
(3) Servicio de Medicina Nuclear, Hospital Vithas-Nisa 9 de Octubre, Valencia, España; Servicio de Medicina Nuclear, Hospital Universitario y Politécnico la Fe, Valencia, España.
(4) Servicio de Medicina Nuclear, Hospital Universitario Virgen del Rocío, Sevilla, España.
(5) Servicio de Medicina Nuclear, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria de Granada (IBS), Granada, España.
(6) Servicio de Medicina Nuclear, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.
(7) Servicio de Medicina Nuclear, Hospital Universitari Son Espases, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, España.
(8) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, Navarra, España.

Revisão:Revista Española de Medicina Nuclear Imagen Molecular

Data: 15/Mai/2018

Medicina Nuclear [ES]

RESUMO

Alzheimer's disease (AD) is a neurodegenerative condition characterized by progressive cognitive decline and memory loss, and is the most common form of dementia.

Amyloid plaques with neurofibrillary tangles are a neuropathological hallmark of AD that produces synaptic dysfunction and culminates later in neuronal loss.

Amyloid PET is a useful, available and non-invasive technique that provides in vivo information about the cortical amyloid burden. In the latest revised criteria for the diagnosis of AD biomarkers were defined and integrated: pathological and diagnostic biomarkers (increased retention on fibrillar amyloid PET or decreased Aβ1-42 and increased T-Tau or P-Tau in CSF) and neurodegeneration or topographical biomarkers (temporoparietal hypometabolism on 18F-FDG PET and temporal atrophy on MRI).

Recently specific recommendations have been created as a consensus statement on the appropriate use of the imaging biomarkers, including amyloid PET: early-onset cognitive impairment/dementia, atypical forms of AD, mild cognitive impairment with early age of onset, and to differentiate between AD and other neurodegenerative diseases that occur with dementia.

Amyloid PET is also contributing to the development of new therapies for AD, as well as in research studies for the study of other neurodegenerative diseases that occur with dementia where the deposition of Aβ amyloid is involved in its pathogenesis. In this paper, we review some general concepts and study the use of amyloid PET in depth and its relationship with neurodegenerative diseases and other diagnostic techniques.

CITAÇÃO DO ARTIGO   Rev Esp Med Nucl Imagen Mol. 2018 May 15. pii: S2253-654X(18)30048-9. doi: 10.1016/j.remn.2018.03.004

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra